{
    "Trade/Device Name(s)": [
        "CKMB UDR Assay",
        "CKMB UDR"
    ],
    "Submitter Information": "SENTINEL CH. SpA",
    "510(k) Number": "K102706",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003158"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHW",
        "JIX",
        "JHS"
    ],
    "Summary Letter Date": "August 10, 2011",
    "Summary Letter Received Date": "August 12, 2011",
    "Submission Date": "August 18, 2011",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatine kinase MB isoenzyme (CK-MB)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Li-heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "UniCel DxC 600 System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunologic inhibition",
        "Kinetic measurement"
    ],
    "Methodologies": [
        "Enzyme inhibition assay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for SENTINEL CKMB UDR assay for quantitative determination of CK-MB activity in serum and Li-heparin plasma using immunologic inhibition on UniCel DxC 600 System",
    "Indications for Use Summary": "In vitro diagnostic test for kinetic quantitative determination of CK-MB isoenzyme activity of creatine kinase in serum and Li-heparin plasma by inhibition method, aiding diagnosis and follow-up of acute myocardial infarction and muscular diseases; for professional use only",
    "fda_folder": "Clinical Chemistry"
}